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Developmental programming of 
polycystic ovary syndrome (PCOS): 
prenatal androgens establish 
pancreatic islet α/β cell ratio and 
subsequent insulin secretion
S. Ramaswamy1, C. Grace1, A. A. Mattei1, K. Siemienowicz2, W. Brownlee1, J. MacCallum1, 
A. S. McNeilly2, W. C. Duncan2 & M. T. Rae1
Exogenous androgenic steroids applied to pregnant sheep programmes a PCOS-like phenotype in 
female offspring. Via ultrasound guidance we applied steroids directly to ovine fetuses at d62 and d82 
of gestation, and examined fetal (day 90 gestation) and postnatal (11 months old) pancreatic structure 
and function. Of three classes of steroid agonists applied (androgen - Testosterone propionate (TP), 
estrogen - Diethystilbesterol (DES) and glucocorticoid - Dexamethasone (DEX)), only androgens (TP) 
caused altered pancreatic development. Beta cell numbers were significantly elevated in prenatally 
androgenised female fetuses (P = 0.03) (to approximately the higher numbers found in male fetuses), 
whereas alpha cell counts were unaffected, precipitating decreased alpha:beta cell ratios in the 
developing fetal pancreas (P = 0.001), sustained into adolescence (P = 0.0004). In adolescence basal 
insulin secretion was significantly higher in female offspring from androgen-excess pregnancies 
(P = 0.045), and an exaggerated, hyperinsulinaemic response to glucose challenge (P = 0.0007) 
observed, whereas prenatal DES or DEX treatment had no effects upon insulin secretion. Postnatal 
insulin secretion correlated with beta cell numbers (P = 0.03). We conclude that the pancreas is a 
primary locus of androgenic stimulation during development, giving rise to postnatal offspring whose 
pancreas secreted excess insulin due to excess beta cells in the presence of a normal number of alpha 
cells.
Polycystic ovary syndrome (PCOS) is one of the most commonly found endocrinopathies in women during 
their reproductive years1. Whilst mechanisms underpinning the developmental route culminating in PCOS in 
women are unclear, animal models designed to recreate PCOS associated pathologies have utilised over-exposure 
of female fetuses/pregnant dams to androgenic steroids2–10. This single intervention recreates both reproductive 
and metabolic features of human PCOS and, given hyperandrogenic states of PCOS sufferers, may also be rep-
licative of the human condition, evidenced by cord blood concentrations of daughters born to PCOS-patients 
exhibiting male ranges of androgens11.
PCOS has an associated raft of metabolic dysfunctions in addition to reproductive phenotypes. Sufferers are 
often more insulin resistant than non-PCOS patients, and as such develop compensatory hyperinsulinaemia4,12. 
However, both our ovine model, and a rhesus monkey model, have indicated that abnormal pancreatic func-
tion likely precedes development of insulin resistance9,10. Additionally, as opposed to simply a compensatory 
response to IR, recent studies place hyperinsulinaemia upstream, and contributory to, diet-induced obesity13. 
Given repeated indications of adult beta cell dysfunction in PCOS patients14,15, and the profound effects that 
insulin has on numerous tissue types, including promotion of ovarian steroidogenesis16, the possibility that the 
pancreas is a primary locus of initial PCOS development with a role in downstream metabolic and reproductive 
dysfunction warrants further investigation.
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Mid-gestational androgenic over-exposure is associated with altered fetal pancreatic beta cell gene expres-
sion, predictive of increased beta cell function/proliferation, and congruent increased in vitro insulin secretion9. 
Increased adolescent offspring beta cell numbers in our maternally androgen exposed model was observed, and 
in line with this a recent series of studies in monkeys observed increased pancreatic beta cell content in infants 
in response to androgenic over-exposure in fetal life10. However, it is uncertain whether or not such beta cell 
proliferation originated during fetal life. Given that effects on the pancreas may reflect a contribution of both 
androgenic effects directly on the pancreas/beta cells, and a transient state of maternal hyperglycaemia associated 
with androgenic treatment of dams10, we developed a complimentary, direct fetal androgen exposure paradigm 
in order to avoid androgenic effects on pregnant dams7,9. Here we test the hypothesis that pancreatic effects of 
androgen over-exposure are direct consequences of androgen-driven developmental alterations, with postnatal 
metabolic consequences underpinned by a permanently altered endocrine pancreatic phenotype.
Materials and Methods
Ethics statement. All studies were approved by the UK Home Office and conducted under approved Project 
Licence PPL 60/4401, reviewed by The University of Edinburgh Animal Research Ethics Committee.
Animals and fetal tissue collection. Mature Scottish Greyface ewes were fed in order to achieve a com-
parable body condition score (2.75–3) prior to estrous cycle synchronisation. After a synchronised mating (Texel 
ram) animals were allocated at random to one of two experimental groups – vehicle control or testosterone propi-
onate (TP) exposed. On day 62 and day 82 of gestation, anaesthesia was induced by initial sedation via adminis-
tration of 10 mg Xylazine i.m (‘Rompun’, Baylor plc Animal Health Division, UK), followed by 2 mg/kg ketamine 
(i.v, Keteset, Fort Dodge Animal Health, UK). All downstream procedures were conducted under surgical aseptic 
conditions. TP was dissolved in vegetable oil (100 mgml−1) and a 200 μ l volume injected (20 G Quinke spinal 
needle, BD Biosciences) via ultrasound guidance into the fetal flank. Control fetuses received 200 μ l vegetable 
oil vehicle alone. In a separate set of studies, TP was replaced with diethylsilbesterol (DES17) or dexamethasone 
(DEX 500 μ gml−1). This procedure was then repeated at d82 of gestation. Immediately after surgical procedure 
completion all pregnant ewes were given prophylactic antibiotics (Streptacare, Animalcare Ltd, UK, 1 ml/25 kg) 
and were then monitored during recovery; no adverse effects of these procedures were observed.
In the case of fetal tissue collection, ewes were sacrificed on d90 of gestation via barbiturate overdose. The 
gravid uterus was immediately exteriorised, fetal sex recorded and fetal pancreatic tissue removed. Each pancreas 
was divided into two portions laterally; one portion was then snap frozen and stored at − 80 °C, the other was 
immersion fixed in Bouins solution for 24 hours, rinsed free of excess Bouins with 70% ethanol, and then stored 
in 70% ethanol prior to processing and paraffin wax embedding for histological analysis.
In experiments where pregnancies carried to term, offspring were lambed and reared conventionally (weaned 
at 3 months postnatal age). Due to economic and practical constraints, only female offspring were studied. Prior 
to sacrifice at 11 months of age, all animals received a bolus injection of glucose (10 g glucose in 20 ml saline), and 
15 minutes post injection sacrifice was achieved via barbiturate overdose. Tissues (pancreas, muscle and liver) 
were recovered and processed for downstream analyses as described for fetal samples.
All animal numbers are given in figure legends. Animal studies utilised twin and singleton pregnancies, but in 
order to avoid any possibility of genetic bias included only one animal from each pregnancy.
Glucose tolerance testing. Animals were fasted overnight and a glucose tolerance test (GTT) performed 
by administering a bolus glucose injection (10 g glucose in 20 ml saline) administered intravenously following 
collection of a basal blood sample. Post-glucose administration, blood was sampled at 15 minute intervals for 
30 minutes.
Plasma analyte determinations. Insulin concentration in blood samples collected during GTT was deter-
mined as previously described9. Insulin ELISA assay sensitivity was 0.14 ng/ml and inter and intra assay CVs were 
< 6% and < 5% respectively. Glucose concentrations were determined via a colorimetric glucose assay kit (Alpha 
Laboratories Ltd., Eastleigh, UK), in combination with a Cobas Fara centrifugal analyzer (Roche Diagnostics Ltd., 
Welwyn Garden City, UK). Assay sensitivity was 0.2 mmol/l and inter and intra assay CVs were < 3% and < 2%, 
respectively.
Examination of Gene Expression by Quantitative (Q) RT-PCR. Frozen fetal pancreas and offspring 
liver and striated muscle was homogenised in RLT buffer (including 2-mercaptoethanol, 1% v/v) (Qiagen, 
Crawley, UK) and RNA was extracted using RNeasy minispin columns following the manufacturer’s protocols, 
including on-column DNaseI digestion (Qiagen, Crawley, UK). RNA concentrations were determined using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK), with Agilent Bioanalyser 
analysis utilised for RNA quality control. Complimentary DNA (cDNA) was synthesised according to kit man-
ufacturer protocols (PrimerDesign Ltd, UK). Previously published and validated primer pairs were used7. 
Quantitative PCR was performed exactly as previously described9, utilising Genorm analysis (PrimerDesign 
Ltd, UK) in order to identify a panel of three stable housekeeping genes – thus the geometric mean of GAPDH, 
ATP5B and ACTB was used as the normalisation reference. Ovine placental cDNA and pooled ovine fetal pan-
creatic cDNA were used as positive controls, and negative controls consisted of an RT-ve and a template negative 
reaction.
Histology. Three sections (5 μ m) were collected from each pancreatic tissue sample, a minimum of 100 μ m 
apart, and mounted on positively charged slides (Superfrost Plus Gold, Thermoscientific, Epsom, UK). Insulin 
and glucagon localisation was performed as previously described9, using anti-insulin mouse monoclonal anti-
body (Abcam, Cambridge, UK; 5 μgml−1) or anti-glucagon rabbit polyclonal antibody (Millipore, UK; 1 in 2000 
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dilution). Negative controls consisted of substitution of primary antibody with mouse IgG or non-immune rabbit 
serum at the same concentration as the respective primary antibodies. In the case of dual fluorescent staining, 
anti-insulin and anti-glucagon antibodies were applied simultaneously (anti-insulin 5μgml−1; anti-glucagon 1 
in 1000 dilution, 2% normal goat serum (NGS) as diluent). Secondary detection reagents consisted of biotiny-
lated goat anti-rabbit (Vector Laboratories, UK, 1 in 500 dilution in 2% NGS) in combination with Dylight 549 
streptavidin (Vector Laboratories, UK, 1 in 100 dilution in 2% NGS) and Alexafluor 488 goat-anti-mouse IgG 
(Life Technologies, UK, 1 in 100 dilution in NGS), followed by washing procedures9 and final mounting in aque-
ous mountant containing DAPI (Vectashield, vector laboratories, UK), prior to visualisation on a Zeiss LSM 880 
AxioObserver Z1 confocal fluorescent microscope (wavelengths: 405 nm, 488 nm, 594 nm, laser power set at 2%).
Cell quantification. Each section generated by standard chromagen immunohistochemistry was subjected 
to quantification by an operator blinded to treatment. Five fields on each section were selected at random, and 
numbers of stained cells within an eye piece grid counted, and a mean count per mm2 derived for each animal.
Western blotting. Western blot analysis of liver and muscle, collected 15 minutes post bolus glucose 
administration at sacrifice was carried out as previously described9. After confirmation of molecular weight by 
molecular weight markers, blots were scanned with an Odyssey® Infrared Imaging System (LI-COR Biosciences, 
Cambridge, UK) using appropriate filters (700/800 nm channel) and proteins bands numerically quantified using 
Image Studio Lite™ v.2.0 software package.
Statistical analyses. All analyses were conducted using GraphPad Prism v6.0 (GraphPad Software Inc., San 
Diego, CA), regarding values of P < 0.05 as significant (alpha = 0.05). Animal numbers are given in figure legends, 
and were based upon previous observations of maternal androgenisation paradigms generating significant, mean-
ingful differences from n = 4–6 per treatment group7–9. Data were logarithmically transformed prior to analysis 
where non-Gaussian distributions were indicated or unequal variabilities indicated by Brown-Forsythe testing. 
Unpaired, two-tailed student t-test was used throughout where only single comparisons were made, multiple 
comparisons were performed by one way ANOVA with Tukeys post-hoc testing utilised for multiple compar-
isons. Area under the curve (AUC) was calculated using the trapezoidal method. Correlation was assessed by 
calculation of the Pearson r co-efficient. Insulogenic index was calculated by published method18.
Results
Direct exposure to testosterone prenatally and insulin secretion in adolescent females. Direct 
injection of androgen into the developing female fetus had no impact on weight at birth (C: 5.8 ± 0.32 kg; 
TP: 5.9 ± 0.27 kg) or adolescence (C: 42.4 ± 3.37 kg; TP: 45.57 ± 3.94 kg). In adolescence basal (fasting) insu-
lin concentrations were mildly elevated (P = 0.045) by prenatal androgen treatment, and there was a markedly 
exaggerated insulin response at both 15 (P = 0.0017) and 30 minutes (P = 0.0009) post-glucose administration 
in ewes which were injected with TP during fetal life as compared to vehicle treated control animals (Fig. 1A). 
Over the duration of the 30 minute GTT there was no difference in AUCglucose (Fig. 1C,D), however AUCinsulin was 
significantly elevated in prenatal TP treated ewes as compared to vehicle controls (P = 0.0007) (Fig. 1B). In female 
offspring hyperinsulinaemia can therefore be directly prenatally programmed by testosterone.
Direct exposure to testosterone prenatally and insulin action in adolescent females. We next 
examined if offspring hyperinsulinaemia was associated with alterations in peripheral insulin reception at a 
molecular level. Western blotting for total and phosphorylated ERK and AKT/PKB was performed on liver and 
muscle biopsies collected 15 minutes post-glucose bolus administration. There were no significant differences 
associated with prenatal treatment in ERK or AKT phosphorylation in either muscle or liver (Table 1). In addition 
we did not observe any significant differences in gene expression of key insulin response genes/glucose transport-
ers in either tissue (Table 1). There is an apparent lack of molecular motifs associated with insulin resistance (IR) 
in the hyperinsulinaemic adolescent female offspring directly exposed to testosterone in utero.
The relationship between hyperinsulinaemia and pancreatic islet morphology in adolescent 
females. Alpha and beta cells in pancreatic islets were identified by immunohistochemistry and quantified. 
Direct fetal injection of TP had no effect on the islet alpha cell content in adolescent females (Fig. 2A,B). However 
there was a marked elevation in the numbers of beta cells in the pancreatic islets of female offspring treated 
with TP prenatally as compared to offspring injected with vehicle control in utero (P = 0.009 × 10−9) (Fig. 2C). 
Consequently direct exposure to excess testosterone prenatally was associated with a decreased alpha:beta cell 
ratio in the pancreatic islets of female offspring in adolescence (P = 0.0004) (Fig. 2D). There was a direct relation-
ship between beta cell numbers and insulin secretion over a 30 minute GTT (Pearson r = 0.6; P = 0.03, Fig. 2E). 
Furthermore, the insulogenic index was elevated in adolescent females who were prenatally injected with TP as 
compared to vehicle-treated controls animals (C: 0.49 ± 0.12; TP 0.76 ± 0.07 (P = 0.034). The increased insulin 
response to glucose is associated with alterations in pancreatic islet morphology.
Sex differences in fetal pancreatic islet development. We next hypothesised that there were differ-
ences in male and female pancreatic development, mediated by androgens, and that prenatal androgens pro-
grammed a male islet phenotype, which was discordant with the postnatal environment. We therefore quantified 
alpha and beta cells numbers in fetal pancreatic islets (Fig. 3A). At day 90 gestation male fetuses have increased 
beta cell numbers when compared to female fetuses (Fig. 3B; ANOVA P = 0.0021, control female vs control male 
P = 0.01). Injection of testosterone into female fetuses resulted in an increase in beta cells (P < 0.05) to male-like 
concentrations suggesting that this increase is androgen dependent (Fig. 3B). Indeed AR expression in the fetal 
pancreas was higher in males than females (MC: 0.89 ± 0.22; FC: 0.35 ± 0.03; P = 0.012) and, as a marker of ‘male’, 
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was increased in females in response to testosterone exposure (FTP 0.51 ± 0.06; P = 0.034). There was no further 
increase in beta cells when male fetuses were injected with testosterone (Fig. 3B).
Figure 1. Prenatal androgen excess alters insulin secretion in adolescent offspring. Intravenous GTT was 
performed on 11 month old female offspring from control (n = 6) and fetal TP exposed (n = 13) pregnancies. 
Basal insulin was elevated slightly in prenatal TP ewes, and an exaggerated response in terms of insulin was 
noted at 15 and 30 minutes post-glucose injection in TP-exposed animals as compared to controls (A), leading 
to significantly increased insulin secretion over the duration of the test as calculated by AUC (B). There were 
no alterations in glucose concentrations at any time point measured after glucose administration (C), and no 
differences in glucose concentration over the duration of the test as measured by AUC (D). (* P < 0.05;  
* * P < 0.01). Data represents mean ± s.e.m.
End point Female control Female TP Significance
Western blot
 Hepatic tERK: pERK 6.88 ± 2.50 8.87 ± 3.74 NS
 SM tERK: pERK 1.01 ± 0.49 1.47 ± 0.87 NS
 Hepatic tAKT: pAKT 0.58 ± 0.16 0.75 ± 0.33 NS
 SM tAKT: pAKT 0.52 ± 0.32 0.66 ± 0.07 NS
qRT-PCR
 Hepatic SLC2A1 2.93 ± 1.02 4.99 ± 1.44 NS
 SM SLC2A1 0.97 ± 0.29 0.82 ± 0.12 NS
 Hepatic SLC2A4 2.61 ± 0.62 3.98 ± 0.92 NS
 SM SLC2A4 0.93 ± 0.2 1.18 ± 0.16 NS
 Hepatic IRS1 4.1 ± 1.43 5.87 ± 1.73 NS
 SM IRS1 0.40 ± 0.19 2.28 ± 0.69 NS
 Hepatic INSR 3.09 ± 0.99 4.58 ± 1.47 NS
 SM INSR 1.02 ± 0.17 0.61 ± 0.09 NS
Table 1.  Insulin signalling-associated gene expression and pathway activation are not altered in adolescent 
female offspring exposed to excess androgen during fetal life. Insulin signalling genes and phosphorylation 
of ERK1/2 and AKT were quantified in a random subset of 11 month old female offspring from control (n = 5) 
and TP treated pregnancies (n = 5), in skeletal muscle (SM) and hepatic tissue samples obtained at sacrifice, 
15 minutes post intravenous glucose bolus administration. There was no significant (NS) effect of TP treatment 
upon any of the end-points quantified. Data represents mean ± s.e.m.
www.nature.com/scientificreports/
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Male fetuses also had a significantly higher number of alpha cells as compared to female fetuses (ANOVA 
P = 0.013, control male vs control female P < 0.001) (Fig. 3C). Thus there were no sex differences in the islet 
alpha:beta cell ratio, which in the day 90 fetal pancreas is approximately 1:1 (Fig. 3D). Direct injection of testos-
terone into female fetuses had no effects upon alpha cell numbers (Fig. 3C). Thus in fetal life direct exposure to 
testosterone alters the female fetal alpha:beta cell ratio in fetal islets as compared to control females (P < 0.01) 
and control males (P < 0.01) (Fig. 3D ANOVA P = 0.0017). This alteration is reminiscent of that observed in the 
adolescent offspring (Fig. 2D).
The effect of other steroid classes on pancreatic islet development and function. We further 
hypothesised that there may be indirect effects of testosterone in the female fetus, either by affecting adrenal 
function or through local metabolism to estrogen, that may be involved in programming islet development. 
Therefore to fully confirm that the effect on the islet development is specific to testosterone we assessed the 
effect of fetal injection of estradiol and cortisol agonists. Direct fetal injection with DES or DEX showed no 
alteration in the fetal pancreatic islet alpha:beta cell ratio, unlike the altered profile caused by direct injection 
of TP (Fig. 4A). In addition there was no alteration in the adolescent female islet β -cell numbers associated 
with DES treatment, however there was a small, but nonetheless statistically significant reduction in adoles-
cent beta cell numbers associated with prenatal DEX treatment (P = 0.01) (Fig. 4B). Only prenatal TP was 
associated with altered insulin secretion in adult life (P < 0.05 as compared to DES and DEX) (Fig. 4C ANOVA 
P = 0.0057).
Figure 2. Prenatal androgen excess and altered pancreatic structure in postnatal offspring underpins 
increased insulin secretion. Representative immunohistochemistry images from 11 month old control and 
direct TP treated female offspring (panel A). Top panels show pancreatic tissue stained for glucagon indicating 
alpha cells. The middle two panels show beta cells after immunostaining for insulin. The lower two panels show 
immunofluorescence of alpha cells (red) and beta cells (green) demonstrating beta cell dominance in islets from 
in utero TP treated offspring as compared to control offspring pancreas tissue at 11 months postnatal age. Scale 
bars = 50 μ m. No effects of prenatal treatment occurred as regards alpha cells (Panel B), but beta cell counts 
were significantly elevated as compared to control animals (Panel C). This depressed the alpha:beta cell ratio 
in TP treated female fetuses (D). There was a significant correlation (P = 0.03) between the amounts of insulin 
secreted over a thirty minute GTT (see Fig. 1) and the number of beta cells quantified (E). (* * * P < 0.001). Data 
represents mean ± s.e.m.
www.nature.com/scientificreports/
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Discussion
PCOS in women is associated with post-pubertal IR development19, thereby promoting compensatory hyper-
insulinaemia4,12. In fetal androgenic over-exposure ovine models, designed to phenocopy diagnostic criteria 
for PCOS, female adolescent offspring hyperinsulinaemic responses to glucose administration are observed in 
the absence of measurable IR7,9. Similarly, excessive insulin secretion (when measured relative to insulin sen-
sitivity) precedes altered insulin sensitivity in (prenatal androgenic over-exposure) monkey models of PCOS5. 
These observations in animal models of PCOS identify the Islets of Langerhans as a potential primary loci 
of downstream metabolic perturbations caused by fetal androgenic over-exposure. Given mechanistic rela-
tionships between insulin excess and ovarian androgen excess16,20, it is critical to understand the aetiological 
relationship between these metabolic and reproductive interfaces in PCOS.
Partial alignment of fetal female pancreatic beta cell-associated gene expression with that seen in fetal males in 
response to androgen-over-exposure commencing in the second trimester has been observed9. Masculinisation of 
hypothalamic function in terms of regulation of energy intake has been observed, and ascribed to prenatal steroid 
differences between males and females during development21. The male beta cell profile noted was likely created 
by endogenous, intra-fetal androgens derived from the developing testes, supported herein by the masculinisa-
tion of pancreatic AR expression in response to androgen excess in the developing female fetus. This, and other 
previously reported gene expression shifts, is predictive of fetal islet development being masculinised by prenatal 
androgen concentrations. However, whilst previous experiments reported structural alterations in postnatal ovine 
pancreases associated with increased maternal testosterone concentrations, fetal antecedents of this phenomenon 
remained equivocal, regardless of fetal gene expression and in vitro insulin secretion being predictive of postna-
tal alterations observed9. Maternal injection of testosterone caused both testosterone and estradiol elevation9, 
and lack of fetal dosage control in maternally applied steroids enhances variability in outcome, hence we have 
re-examined the fetal pancreas in a controlled, direct fetal steroid injection model.
Fetal males had significantly greater numbers of both alpha and beta cells than females. Alpha cell counts were 
unaltered by over-exposure to TP during female fetal development, and thus if testicular androgens configured 
alpha cell proliferation in males then sensitivity to androgens is diminished by mid gestation. Conversely, beta 
cell numbers, higher in males than in females, were elevated in exposed female fetuses to a similar profile to that 
of males, hence our androgen treatment regimen specifically masculinised the beta cell profile alone. We have 
Figure 3. Sex differences in fetal pancreatic development are partially recreated by prenatal androgen 
excess in females. Immunohistochemistry images highlighting staining (brown) for insulin (beta cells) and 
glucagon (alpha cells) in female and male fetal pancreatic islets (Panel A). Quantification of immunostained 
pancreatic beta (B) and alpha (C) cells respectively, in d90 gestation fetuses from control (FC: n = 5, MC n = 5) 
and TP treated (FTP: n = 5, MTP n = 5) female and male fetuses. Male fetuses had significantly higher numbers 
of both alpha and beta cells than female fetuses, however TP treated females had a similar beta cell profile to 
males. This in turn depressed the alpha:beta cell ratio in TP treated female fetuses (D). Differing superscripts 
indicate significant differences (P < 0.01− P < 0.001, see text for details). Data represents mean ± s.e.m.
www.nature.com/scientificreports/
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previously demonstrated ovine fetal beta cells to express androgen receptors9, and since this was direct fetal 
administration of TP it would appear that this is a direct androgenic effect; in this regard testosterone can act in 
an anti-apoptotic protective manner towards beta cells22, in addition to predicted pro-proliferative effects from 
gene expression analyses9.
There was no effect in fetal males in terms of altered islet cell numbers in response to TP over-exposure, pre-
sumably since the male has a ‘buffering capacity’ against exogenous androgens, via suppression of endogenous 
T production from the testes17. Importantly, regardless of absolute cell number differences between sexes, both 
control male and control female ovine fetal pancreases display an approximately 1:1 alpha:beta cell ratio, which 
is markedly reduced by direct androgenic over-exposure in female fetuses. This 1:1 alpha:beta cell ratio is also 
apparent in female rhesus monkey infants, and their alpha:beta cell ratio is perturbed in a similar fashion to that 
observed here, in response to prenatal, maternal androgen excess10.
Critically, both routes of androgen administration, indirect maternal and direct fetal, culminate in similar 
pancreatic postnatal outcomes, but here, using the reductive approach of direct fetal exposure, we reveal altera-
tions in fetal life that underpin the observed postnatal outcomes, attributable to excess androgen. Since maternal 
androgen excess models utilising rhesus monkeys10 and sheep9, both also indicated altered islet size, then this 
combined with the similarly perturbed alpha:beta cell ratios in both sheep and monkey models during early 
Figure 4. Altered pancreatic structure and function in female offspring is specifically associated with 
prenatal androgen excess only. When experiments were repeated substituting DEX (n = 4) or DES (n = 4) in 
place of TP, there was no alteration in fetal alpha:beta cell ratio associated with either treatment when compared 
to control (vehicle treated) animals (n = 5) (Panel A). In adolescence, in utero DES (n = 4) treatment was not 
associated with altered beta cell numbers, however, there was a small decrease in beta cell numbers associated 
with DEX (n = 9) treatment in utero as compared to (vehicle) control animals (n = 6) (B). Panel C shows the 
fold change against vehicle controls in AUC insulin secretion over a 30 minute GTT. Of the three steroid classes 
examined, only prenatal androgens elicited a significant change in insulin secretion. (* P < 0.05). Data represents 
mean ± s.e.m.
www.nature.com/scientificreports/
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postnatal life further validates ovine models in terms of the ‘gold standard’ non-human primate model, and 
thus human translation, however, we acknowledge that in utero steroid environments may differ to some extent 
between sheep and humans, principally due to differences in the functional steroidogenic maturation and pitui-
tary drive of the adrenal cortex between these two species23,24.
In order to comprehend longevity and health-relevance of androgen-excess fetal life perturbations, we ana-
lysed alpha and beta cell populations in postnatal (11 month) adolescent offspring. The androgenised fetal beta 
cell pancreatic phenotype persisted throughout early postnatal life and beyond puberty, with similar reductions 
in alpha:beta cell ratios. In both fetal and postnatal life, effects upon pancreatic structure/beta cell numbers were 
specifically a response to excess androgens. Whilst maternal androgenisation culminates in increased fetal andro-
gen and estrogen concentrations we observed no effects of DES on fetal alpha:beta cell ratio or postnatal beta cell 
numbers. Prenatal DEX treatment was associated with a modest reduction in postnatal beta cell numbers. The 
potential significance of this remains unknown, however, the importance herein is that since DEX is associated 
with decreased beta cells, the aforementioned androgenic effects are direct, not associated with either metabolism 
of androgens or altered fetal adrenal function.
We were unable to detect development of IR at a molecular level in the liver or striated muscle. Altered insu-
lin signalling in PCOS, (Ras-ERK phosphorylation) has been reported and linked to IR/hyperinsulinaemia25. 
However we did not observe any significant alterations in genes encoding glucose transporters or insulin signal-
ling molecules in muscle or liver, or indeed insulin signalling alterations in terms of phosphorylation of insulin 
receptor MAPK or AKT/PKB signalling pathways, in line with our previous observations9. Nicol et al. noted 
that in later postnatal life altered cell ratio’s observed in prenatally androgenised rhesus monkey infants were no 
longer present10. Given that these monkeys are by this stage of their lives insulin resistant, and our sheep are not, 
we hypothesise that the altered beta cell profile we observe in early adulthood reflects a pancreas altered in fetal 
life, but as yet not placed under any metabolic pressure from developing IR.
PCOS patients display greater compensatory insulin responses to IR, leading to the suggestion that beta cell 
hypersecretion may be a primary PCOS characteristic that then interacts with developing IR14. IR-corrective 
weight reduction does not correct insulin hypersecretion to the same degree26, implying that hypersecretion 
of insulin may be an initial alteration in PCOS in addition to, but independent of, IR-induced beta cell com-
pensation, persisting even when IR has been largely ameliorated. To ascertain whether or not the histological 
observations noted above in fetal and postnatal life have functional causatum, an intravenous GTT analysis 
was conducted on adolescent offspring. This revealed an exaggerated insulin response in the animals who were 
directly prenatally androgenised, whereas increased estrogenic or glucocorticoid exposure in utero had no 
effects upon postnatal insulin concentrations. Basal insulin, and glucose-stimulated AUCinsulin was significantly 
increased in TP treated animals, with no attendant alteration in glucose profiles. We suggest that increased beta 
cell content underpins this exaggerated insulin response. In support, insulogenic index was increased in adoles-
cent offspring animals from prenatal androgenisation regimens, and we note a correlation between beta cell num-
bers and AUCinsulin. Insulogenic index is also raised in women with PCOS as compared to non-PCOS patients, 
irrespective of obesity status27, and early insulin response to glucose elevated in PCOS, and resolvable from IR28, 
although it is acknowledged that there are conflicting reports of insulin secretion in PCOS18.
We previously demonstrated that the fetal pancreas from androgen overexposed (maternal and/or fetal 
administration) animals secreted excessive insulin to a fixed glucose challenge in vitro9, thus this functional char-
acteristic is established in utero, and, via permanent pancreatic structural change, persists on into postnatal life. 
In terms of the aetiology of altered insulin/glucose dynamics, reductions in insulin sensitivity do not manifest in 
daughters of PCOS patients until after puberty, where although fasting insulin was not raised, 2 h-post glucose 
challenge insulin secretion is higher in girls whose mothers have PCOS19, indicative that altered insulin secretory 
response may also precede onset of IR in humans.
Since hyperinsulinaemia likely precedes IR development in girls born to PCOS mothers19, and antecedes 
IR in both ovine and monkey10 in utero androgen exposure models, it begs the question of whether hyper-
insulinaemia could be a causative factor in the sequelae of events culminating in IR development. Excess, 
sustained insulin concentrations may predispose to development of IR29. Intriguingly, a series of studies uti-
lising ovine maternal-androgen exposure regimens report increased insulin sensitivity at 16 months of age 
in T-exposed female offspring30, which converted to an IR state by 22 months of age31. We hypothesise that 
androgen-programmed (primary) hyperinsulinaemia may therefore act as a contribution in promotion of initial 
IR development. Further study is required to resolve the relative contributions of primary hyperinsulinaemia, IR 
development and subsequent compensatory hyperinsulinaemia in development of glucose intolerance, particu-
larly in light of current evidence implicating hyperinsulinaemia causally to the development of obesity13.
In conclusion, these experiments demonstrate that androgen overexposure has a direct and permanent effect 
in terms of increased beta cell numbers in female pancreases. The outcome of this partial masculinisation of islets 
is altered pancreatic function, delivering a primary hyperinsulinaemic response to glucose. We identify the pan-
creas as a primary loci of downstream effects of fetal androgen overexposure, and demonstrate that the prenatal 
steroid environment is an important driver of future metabolic health.
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